EGFR and cancer: Treatment of HNSCC cells and xenografts with the combination of antibodies to IGF-1R and EGFR was more effective than either agent alone at reducing cancer cell growth [56], suggesting a potential benefit in the use of combined anti-tyrosine kinase receptor directed therapies to treat HNSCC.